Guardant Health, a startup company formed in 2012 by two former Illumina employees, recently announced its first product — a targeted next-gen sequencing-based assay that assesses circulating tumor DNA.
The test, Guardant 360, analyzes 54 oncogenes and tumor suppressor genes. It requires a patient blood sample and uses a proprietary target capture to zero in on the specified genes. Sequencing is done on Illuumina's HiSeq 2500 and turnaround time is two weeks. The company has not yet disclosed a price for its test, which is currently available via early access.